A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

This selectivity may allow for broad spectrum PI3Kα mutation coverage including targeting both H1047X and E545/542X classes of driver mutations in breast cancer and other solid tumor indications.

Potential Positives. Updated interim clinical data for RLY-2608 show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- metastatic ...

That work, published last month in PNAS, showed how some segments of the mutated PI3Kα resemble the activated form of PI3Kα. "There are quite dramatic structural changes," says Vogt.

As a contender in precision oncology, Relay Therapeutics (NASDAQ:RLAY) employs computational modeling to develop selective small-molecule inhibitors.Its flagship PI3Kα inhibitor RLY-2608 and ...

PI3Kα mutations are among the most prevalent drivers of cancer, occurring in over 166,000 patients per year with breast, gynecological and head and neck cancers in the United States alone.

RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company’s RLY-4008 targets FGFR2-altered cholangiocarcinoma, ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company ...

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the ...